The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data
暂无分享,去创建一个
Li Peng | Chaoyang Zhang | Li Peng | Chaoyang Zhang | Guancheng Li | Shilian Chen | Yaqin Zhang | Zhaoyang Liu | Wenling Li | Shilian Chen | Guancheng Li | Wen-ling Li | Z. Liu | Yaqin Zhang
[1] Adrian V. Lee,et al. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling. , 2011, The Journal of clinical investigation.
[2] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[3] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.
[4] Benjamin M. Bolstad,et al. affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..
[5] J. Massagué,et al. Cancer Metastasis: Building a Framework , 2006, Cell.
[6] T. Greten,et al. The yin and yang of evasion and immune activation in HCC. , 2015, Journal of hepatology.
[7] M. Goggins,et al. Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling , 2005, Clinical Cancer Research.
[8] E. Chevet,et al. Integrated endoplasmic reticulum stress responses in cancer. , 2007, Cancer research.
[9] A. Parsa,et al. Complement anaphylatoxins as immune regulators in cancer , 2014, Cancer medicine.
[10] I. Macdonald,et al. Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.
[11] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[12] Steve Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[13] A. Gerger,et al. Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. , 2015, Anticancer research.
[14] A. Jemal,et al. Global Cancer Statistics , 2011 .
[15] K. Katanoda,et al. Five-year relative survival rate of liver cancer in the USA, Europe and Japan. , 2014, Japanese journal of clinical oncology.
[16] A. Jemal,et al. Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.
[17] Bin Nan,et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. , 2007, Cancer research.
[18] B. Rini,et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. , 2011, International immunopharmacology.
[19] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[20] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[21] R. Fisher,et al. Genes Involved in Viral Carcinogenesis and Tumor Initiation in Hepatitis C Virus-Induced Hepatocellular Carcinoma , 2009, Molecular medicine.
[22] C. Coulouarn,et al. Hepatocyte growth factor, transforming growth factor α, and their receptors as combined markers of prognosis in hepatocellular carcinoma , 2003 .
[23] Laurie H Glimcher,et al. The unfolded protein response: integrating stress signals through the stress sensor IRE1α. , 2011, Physiological reviews.
[24] Y. Watanabe,et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. , 2008, Liver.
[25] G. Tamma,et al. Oxidative Medicine and Cellular Longevity , 2017 .
[26] L. Hendershot,et al. The role of the unfolded protein response in tumour development: friend or foe? , 2004, Nature Reviews Cancer.
[27] D. Quiceno,et al. L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.
[28] C. Coulouarn,et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. , 2003, Molecular carcinogenesis.
[29] Crispin J. Miller,et al. Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis , 2005, Bioinform..
[30] John D Lambris,et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. , 2012, Neoplasia.
[31] Sahil Mittal,et al. Epidemiology of hepatocellular carcinoma: consider the population. , 2013, Journal of clinical gastroenterology.
[32] J. Cai,et al. Prognostic value of the albumin–bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.
[33] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[34] M. Plummer,et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.
[35] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[36] Gerhard Christofori,et al. Distinct mechanisms of tumor invasion and metastasis. , 2007, Trends in molecular medicine.
[37] K. Baggerly,et al. Autocrine Effects of Tumor-Derived Complement , 2014, Cell reports.
[38] Arnaud M. Vigneron,et al. The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. , 2008, Cancer research.
[39] W. Leonard,et al. Interleukin-21: a double-edged sword with therapeutic potential , 2014, Nature Reviews Drug Discovery.
[40] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[41] S. Horvath,et al. Evidence for anti-Burkitt tumour globulins in Burkitt tumour patients and healthy individuals. , 1967, British Journal of Cancer.
[42] Cynthia Gibas,et al. Background correction using dinucleotide affinities improves the performance of GCRMA , 2008, BMC Bioinformatics.
[43] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[44] Hans Skovgaard Poulsen,et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. , 2007, Cellular signalling.
[45] P. Schirmacher,et al. Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer. , 2017, The American journal of pathology.
[46] A. Klein-Szanto,et al. IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. , 2014, American journal of cancer research.
[47] C. Koumenis. ER stress, hypoxia tolerance and tumor progression. , 2006, Current molecular medicine.